TY - JOUR T1 - Effect of tumour necrosis factor α blockade on bone metabolism in chronic inflammatory joint diseases JO - Medicina Clínica (English Edition) T2 - AU - Aguilar del Rey,Francisco Javier AU - García Portales,Rosa AU - Haro Liger,Manuel AU - Rodríguez Andreu,José AU - Casals Sánchez,José Luis AU - Pérez González,Rita SN - 23870206 M3 - 10.1016/j.medcle.2016.09.005 DO - 10.1016/j.medcle.2016.09.005 UR - https://www.elsevier.es/en-revista-medicina-clinica-english-edition--462-articulo-effect-tumour-necrosis-factor--S2387020616304958 AB - Background and objectiveTo evaluate the effect of anti-TNF treatments on bone mineral density (BMD), bone remodelling markers (BRM) and receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) in patients with chronic inflammatory joint diseases. MethodsA longitudinal prospective study was performed under clinical practice conditions on 31 patients diagnosed of rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis who had received treatment with anti-TNF alpha drugs for one year. BMD, OPG and RANKL soluble form (sRANKL) were studied at the onset and end of the study. During the study (0, 3, 6, 9 and 12 month), disease activity (SDAI, BASDAI and CRP), functional capacity (HAQ, BASFI), BRM and vitamin D were studied. ResultsBMD was not modified after one year of treatment. The patients who took corticosteroids had a mean bone mass loss of 3% in the lumbar spine (±1.6, p=.02). In regards to the BRM, did not experience significant changes over the course of the study. Disease activity, both SDAI (p=.002) and BASDAI (p=.002), decreased. OPG was maintained without changes during the year of treatment while both the sRANKL (0.28±0.22, p=.013) and sRANKL/OPG ratio significantly decreased (0.04±0.03, p=.031). ConclusionThe patients being treated with anti-TNF did not present with a significant loss of DMO during the study (one year), at the same time experiencing an improvement in disease activity. This protection has been clearer in the responding patients. ER -